{"id":464,"date":"2026-08-28T06:56:05","date_gmt":"2026-08-28T06:56:05","guid":{"rendered":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"elamipretide-barth-syndrome-trial-fda-accelerated-approval","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/de\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/","title":{"rendered":"Elamipretid beim Barth-Syndrom: Was die 12-Patientenstudie und die FDA-Aufzeichnung zeigen"},"content":{"rendered":"

Elamipretide verf\u00fcgt nun \u00fcber ein von FDA zugelassenes Endprodukt f\u00fcr eine enge Indikation des Barth-Syndroms, die Zulassung basiert jedoch auf einem ungew\u00f6hnlichen Datensatz zu seltenen Krankheiten. Der randomisierte Teil umfasste 12-Teilnehmer und erreichte nicht seine beiden prim\u00e4ren Endpunkte.<\/p>

Was die Aufzeichnung zeigt<\/h2>
  • Alle randomisierten 12-Teilnehmer waren m\u00e4nnlich im Alter von 12 bis 35 Jahren an einem US-Standort.<\/li>
  • Die randomisierte Studie zeigte keine \u00dcberlegenheit bei den prim\u00e4ren Endpunkten 6-Gehminuten oder M\u00fcdigkeit.<\/li>
  • FDA erteilte eine beschleunigte Zulassung auf der Grundlage der w\u00e4hrend l\u00e4ngerer, offener Nachuntersuchungen beobachteten Kniestreckkraft und erforderte eine Best\u00e4tigungsstudie.<\/li><\/ul><\/div><\/div>
    \"Wissenschaftler
    Originale redaktionelle Darstellung des Forschungskontexts. Es handelt sich nicht um eine Studienfigur, ein Patientenbild, ein Produktfoto oder eine Darstellung von Versuchsmaterial.<\/figcaption><\/figure>

    Studienprotokoll<\/h2>

    Die Crossover-Studie verglich 12-w\u00f6chige Perioden mit Elamipretid und Placebo, getrennt durch Auswaschen. Zehn Teilnehmer nahmen an der Open-Label-Verl\u00e4ngerung teil und acht wurden bis zur Woche 168 beobachtet.<\/p>

    Randomisierte Population<\/strong>12 genetisch best\u00e4tigte Barth-Syndrom-Patienten<\/span><\/div>
    Prim\u00e4re Endpunkte<\/strong>6-Minuten-Gehstrecke und Gesamterm\u00fcdungswert<\/span><\/div>
    Prim\u00e4res Ergebnis<\/strong>Keiner der Endpunkte wurde im randomisierten Crossover-Teil erreicht<\/span><\/div>
    Genehmigungsdatum<\/strong>19. September 2025<\/span><\/div>
    Genehmigungstyp<\/strong>Beschleunigt; Best\u00e4tigungsversuch erforderlich<\/span><\/div><\/div><\/div>

    Ergebnisse im Kontext<\/h2>

    FDA gibt eine mittlere Grundst\u00e4rke der Kniestrecker von 124 Newton an. Die mittleren Ver\u00e4nderungen in Woche 12 betrugen \u22125 Newton unter Placebo und +4 unter Elamipretid; W\u00e4hrend der Open-Label-Verl\u00e4ngerung traten gr\u00f6\u00dfere beschreibende \u00c4nderungen auf, darunter +63 Newton bei acht Teilnehmern in der Woche 168.<\/p>

    Offene Ver\u00e4nderungen sind anf\u00e4llig f\u00fcr Zeiteffekte, Erwartungen, selektive Fortsetzung und das Fehlen einer gleichzeitigen Kontrolle. FDA ben\u00f6tigte daher nach der Zulassung eine Best\u00e4tigung, dass sich die Festigkeits\u00e4nderung in einem Nutzen f\u00fcr den Patienten niederschl\u00e4gt.<\/p>

    Was diese Studie nicht beantworten kann<\/h2>

    Der Datensatz ist extrem klein und unterst\u00fctzt keine Untergruppenanalyse.<\/p>

    Die Zulassung gilt f\u00fcr Forzinity f\u00fcr Patienten mit Barth-Syndrom mit einem Gewicht von mindestens 30 kg \u2013 nicht f\u00fcr generische \u201eSS-31\u201c-Materialien oder andere Verwendungszwecke.<\/p>","protected":false},"excerpt":{"rendered":"

    Elamipretide verf\u00fcgt nun \u00fcber ein von FDA zugelassenes Endprodukt f\u00fcr eine enge Indikation des Barth-Syndroms, die Zulassung basiert jedoch auf einem ungew\u00f6hnlichen Datensatz zu seltenen Krankheiten. Der randomisierte Teil umfasste 12-Teilnehmer und erreichte nicht seine beiden prim\u00e4ren Endpunkte.<\/p>","protected":false},"author":1,"featured_media":629,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"364","pim_article_type":"Published study case","pim_evidence_level":"Small randomized crossover trial plus FDA accelerated-approval record","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"FDA Drug Trials Snapshot: Forzinity\",\"url\":\"https:\/\/www.fda.gov\/drugs\/drug-trials-snapshots\/drug-trials-snapshots-forzinity\",\"note\":\"Trial population, endpoint results and approval basis.\"},{\"title\":\"Elamipretide phase 2\/3 Barth syndrome crossover trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33077895\/\",\"note\":\"Primary published trial; PMID 33077895.\"},{\"title\":\"FDA accelerated approval announcement for Forzinity\",\"url\":\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-treatment-barth-syndrome\",\"note\":\"Approval scope and confirmatory requirement.\"}]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-464","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"\nElamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show - NHD<\/title>\n<meta name=\"description\" content=\"Elamipretide now has an FDA-approved finished product for a narrow Barth syndrome indication, but the approval rests on an unusual rare-disease dataset. Th\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/de\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show\" \/>\n<meta property=\"og:description\" content=\"Elamipretide now has an FDA-approved finished product for a narrow Barth syndrome indication, but the approval rests on an unusual rare-disease dataset. Th\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/de\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T06:56:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/\"},\"wordCount\":284,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/\",\"name\":\"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"Elamipretide now has an FDA-approved finished product for a narrow Barth syndrome indication, but the approval rests on an unusual rare-disease dataset. Th\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/de\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Elamipretid beim Barth-Syndrom: Was die 12-Patientenstudie und die FDA-Aufzeichnung zeigen - NHD","description":"Elamipretide verf\u00fcgt nun \u00fcber ein von FDA zugelassenes Endprodukt f\u00fcr eine enge Indikation des Barth-Syndroms, die Zulassung basiert jedoch auf einem ungew\u00f6hnlichen Datensatz zu seltenen Krankheiten. Das\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/de\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/","og_locale":"de_DE","og_type":"article","og_title":"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show","og_description":"Elamipretide now has an FDA-approved finished product for a narrow Barth syndrome indication, but the approval rests on an unusual rare-disease dataset. Th\u2026","og_url":"https:\/\/nhdbio.com\/de\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/","og_site_name":"NHD","article_published_time":"2026-08-28T06:56:05+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Verfasst von":"NHD Technical Team","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/"},"wordCount":284,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp","articleSection":["Published Study Reviews"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/","url":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/","name":"Elamipretid beim Barth-Syndrom: Was die 12-Patientenstudie und die FDA-Aufzeichnung zeigen - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"Elamipretide verf\u00fcgt nun \u00fcber ein von FDA zugelassenes Endprodukt f\u00fcr eine enge Indikation des Barth-Syndroms, die Zulassung basiert jedoch auf einem ungew\u00f6hnlichen Datensatz zu seltenen Krankheiten. Das\u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Peptidrohstoffe und individuelle Peptidsynthese","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"NHD Technisches Team","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"Das technische Team von NHD verwaltet Katalogdokumentationen und Beweiszusammenfassungen f\u00fcr Forschungszwecke. Rezensierte Artikel verweisen auf von Experten begutachtete Artikel, Studienregister und beh\u00f6rdliche Aufzeichnungen, behalten Nullergebnisse und Studieneinschr\u00e4nkungen bei und unterscheiden ver\u00f6ffentlichte Interventionen von Katalogmaterialien. F\u00fcr die Strukturierung kann AI-unterst\u00fctztes Zeichnen verwendet werden; Quellenverkn\u00fcpfungen und Beweisgrenzen bleiben sichtbar. Bei dieser Arbeit handelt es sich nicht um eine unabh\u00e4ngige Begutachtung oder medizinische Beratung.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/de\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/comments?post=464"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/464\/revisions"}],"predecessor-version":[{"id":512,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/464\/revisions\/512"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media\/629"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media?parent=464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/categories?post=464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/tags?post=464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}